New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml); sodium ioxaglate 19.65%{relative} - solution for injection - 320 mg/ml - active: meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml) sodium ioxaglate 19.65%{relative} excipient: sodium calcium edetate, hydrate water for injection - low osmolar x-ray contrast medium for the opacification of the vascular system, urinary tract, joints and female genital tract. hysterosalpingography

United States - English - NLM (National Library of Medicine)

rebel distributors corp - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 40 mg - therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. in hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium is indicated to: - reduce the risk of myocardial infarction - reduce the risk of undergoing myocardial revascularization procedures - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated total-c, ldl-c, apo b, and tg levels and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).8 pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (fredrickson type iv). pravastatin sodium tabl

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 80 mg - therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. primary prevention of coronary events in hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: – reduce the risk of myocardial infarction – reduce the risk of undergoing myocardial revascularization procedures - reduce the risk of cardiovascular mortality with no increase in death from non- cardiovascular causes. hyperlipidemia pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated total-c, ldl-c, apo b, and tg levels and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).2 pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum tri

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - meglumine; sodium hydroxide ; sodium amidotrizoate - solution for infusion - 30 percent weight/volume - diatrizoic acid

Israel - English - Ministry of Health

promedico ltd - meglumine ioxitalamate - solution for injection - meglumine ioxitalamate 66.03 g / 100 ml - meglumine antimonate - meglumine antimonate - for urograph, selective angiography, peripheral angiography, arthrography, hysterosalpingography and digestive exploration.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; water for injections; meglumine - using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement: . in intracranial and spinal lesions in adults and children with abnormal blood-brain barrier, or abnormal vascularity; . in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis). indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pan

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine 660 mg in 1 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 260 mg/ml (formed from melgumine and amidotrizoic acid); sodium amidotrizoate 40 mg/ml (formed from sodium hydroxide and amidotrizoic acid) - solution for infusion - 30 % - active: meglumine amidotrizoate 260 mg/ml (formed from melgumine and amidotrizoic acid) sodium amidotrizoate 40 mg/ml (formed from sodium hydroxide and amidotrizoic acid) excipient: sodium calcium edetate water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; meglumine; water for injections - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).